A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of VAL-339851 in Healthy Subjects
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs MRNA 1851 (Primary)
- Indications Influenza A virus H7N9 subtype
- Focus Adverse reactions; First in man
- Sponsors Moderna Therapeutics
- 07 Jan 2021 Status changed from active, no longer recruiting to completed.
- 16 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Feb 2020.
- 16 Jan 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Feb 2020.